Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 domain-binding glutamic acid-rich-like protein (SH3BGRL) is a small adapter protein encoded by the SH3BGRL gene on the X chromosome. It belongs to the SH3BGR family, which features a thioredoxin-like protein fold and includes proline-rich regions that mediate protein-protein and possible protein-RNA interactions. SH3BGRL acts as an adapter, bridging proteins or proteins with mRNAs, and may serve as a ubiquitin ligase-substrate adapter. It is involved in positive regulation of cytoplasmic translational initiation and in the proteasome-mediated, ubiquitin-dependent protein catabolic process. Its expression has been noted in various tissues, and it has been associated with some cancers, such as breast cancer, though it is not currently established as a therapeutic target. There are currently no known drugs that specifically target SH3BGRL, and it is not widely recognized as a biomarker or subject to notable safety concerns[1][2][5][6][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3 domain-binding glutamic acid-rich-like protein (SH3BGRL).